Clinical Trial Update: Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer [EARLY_Phase 1]

View source ↗

Summary

Early-phase clinical trial evaluating 177Lu-LNC1004 injection for FAP-positive, radioiodine-refractory differentiated thyroid cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer
• Radioiodine-refractory Differentiated Thyroid Cancer

Drugs mentioned

• 177Lu-LNC1004 Injection (177Lu-LNC1004)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Radioiodine Refractory Differentiated Thyroid Cancer | EARLY_Phase 1 | Status: RECRUITING